Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Gail J. Roboz(NewYork–Presbyterian Hospital), Patricia Kropf(Jeanes Hospital), Karen Yee(Princess Margaret Cancer Centre), Casey L. O’Connell(USC Norris Comprehensive Cancer Center), Raoul Tibes(Mayo Clinic in Arizona), Katherine Walsh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nikolai A. Podoltsev(Yale University), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), David A. Rizzieri(Duke Medical Center), Wendy Stock(University of Chicago), Michael R. Savona(Vanderbilt University Medical Center), Todd Rosenblat(Columbia University Irving Medical Center), Jesús G. Berdeja(Sarah Cannon), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Edwin P. Rock(Astex Pharmaceuticals), Yong Hao(Astex Pharmaceuticals), Mohammad Azab(Astex Pharmaceuticals), Jean‐Pierre J. Issa(Temple University)
Cited by 154Open Access